Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,097 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso PM, Alonso G, Rodriguez-Ruiz ME, Schoedel KB, Blum JM, Sänger B, Salcedo TW, Burm SM, Stanganello E, Verzijl D, Vascotto F, Sette A, Quinkhardt J, Plantinga TS, Toker A, van den Brink EN, Fereshteh M, Diken M, Satijn D, Kreiter S, Breij ECW, Bajaj G, Lagkadinou E, Sasser K, Türeci Ö, Forssmann U, Ahmadi T, Şahin U, Jure-Kunkel M, Melero I. Muik A, et al. Among authors: sette a. Cancer Discov. 2022 May 2;12(5):1248-1265. doi: 10.1158/2159-8290.CD-21-1345. Cancer Discov. 2022. PMID: 35176764 Free PMC article. Clinical Trial.
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.
Edwards CJ, Sette A, Cox C, Di Fiore B, Wyre C, Sydoruk D, Yadin D, Hayes P, Stelter S, Bartlett PD, Zuazo M, Garcia-Granda MJ, Benedetti G, Fiaska S, Birkett NR, Teng Y, Enever C, Arasanz H, Bocanegra A, Chocarro L, Fernandez G, Vera R, Archer B, Osuch I, Lewandowska M, Surani YM, Kochan G, Escors D, Legg J, Pierce AJ. Edwards CJ, et al. Among authors: sette a. Br J Cancer. 2022 May;126(8):1168-1177. doi: 10.1038/s41416-021-01684-4. Epub 2021 Dec 30. Br J Cancer. 2022. PMID: 34969998 Free PMC article.
hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.
Lastraioli E, Perrone G, Sette A, Fiore A, Crociani O, Manoli S, D'Amico M, Masselli M, Iorio J, Callea M, Borzomati D, Nappo G, Bartolozzi F, Santini D, Bencini L, Farsi M, Boni L, Di Costanzo F, Schwab A, Onetti Muda A, Coppola R, Arcangeli A. Lastraioli E, et al. Among authors: sette a. Br J Cancer. 2015 Mar 17;112(6):1076-87. doi: 10.1038/bjc.2015.28. Br J Cancer. 2015. PMID: 25719829 Free PMC article.
Next-generation IEDB tools: a platform for epitope prediction and analysis.
Yan Z, Kim K, Kim H, Ha B, Gambiez A, Bennett J, de Almeida Mendes MF, Trevizani R, Mahita J, Richardson E, Marrama D, Blazeska N, Koşaloğlu-Yalçın Z, Nielsen M, Sette A, Peters B, Greenbaum JA. Yan Z, et al. Among authors: sette a. Nucleic Acids Res. 2024 May 23:gkae407. doi: 10.1093/nar/gkae407. Online ahead of print. Nucleic Acids Res. 2024. PMID: 38783079
SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire.
Tarke A, Ramezani-Rad P, Alves Pereira Neto T, Lee Y, Silva-Moraes V, Goodwin B, Bloom N, Siddiqui L, Avalos L, Frazier A, Zhang Z, da Silva Antunes R, Dan J, Crotty S, Grifoni A, Sette A. Tarke A, et al. Among authors: sette a. Cell Rep Med. 2024 May 17:101583. doi: 10.1016/j.xcrm.2024.101583. Online ahead of print. Cell Rep Med. 2024. PMID: 38781962 Free article.
High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.
Mentzer AJ, Dilthey AT, Pollard M, Gurdasani D, Karakoc E, Carstensen T, Muhwezi A, Cutland C, Diarra A, da Silva Antunes R, Paul S, Smits G, Wareing S, Kim H, Pomilla C, Chong AY, Brandt DYC, Nielsen R, Neaves S, Timpson N, Crinklaw A, Lindestam Arlehamn CS, Rautanen A, Kizito D, Parks T, Auckland K, Elliott KE, Mills T, Ewer K, Edwards N, Fatumo S, Webb E, Peacock S, Jeffery K, van der Klis FRM, Kaleebu P, Vijayanand P, Peters B, Sette A, Cereb N, Sirima S, Madhi SA, Elliott AM, McVean G, Hill AVS, Sandhu MS. Mentzer AJ, et al. Among authors: sette a. Nat Med. 2024 May;30(5):1384-1394. doi: 10.1038/s41591-024-02944-5. Epub 2024 May 13. Nat Med. 2024. PMID: 38740997 Free PMC article.
A pediatric randomized, controlled trial of German cockroach subcutaneous immunotherapy.
Zoratti E, Wood R, Pomés A, Da Silva Antunes R, Altman MC, Benson B, Wheatley LM, Cho K, Calatroni A, Little FF, Pongracic J, Makhija M, Khurana Hershey GK, Sherenian MG, Rivera-Spoljaric K, Stokes JR, Gill MA, Gruchalla RS, Chambliss J, Liu AH, Kattan M, Busse PJ, Bacharier LB, Sheehan W, Kim H, Glesner J, Gergen PJ, Togias A, Baucom JL, Visness CM, Sette A, Busse WW, Jackson DJ; Inner-City Asthma and Childhood Asthma in Urban Settings Consortia. Zoratti E, et al. Among authors: sette a. J Allergy Clin Immunol. 2024 May 6:S0091-6749(24)00455-X. doi: 10.1016/j.jaci.2024.04.022. Online ahead of print. J Allergy Clin Immunol. 2024. PMID: 38718950
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.
Jackson S, Marshall JL, Mawer A, Lopez-Ramon R, Harris SA, Satti I, Hughes E, Preston-Jones H, Cabrera Puig I, Longet S, Tipton T, Laidlaw S, Doherty RP, Morrison H, Mitchell R, Tanner R, Ateere A, Stylianou E, Wu MS, Fredsgaard-Jones TPW, Breuer J, Rapeport G, Ferreira VM, Gleeson F, Pollard AJ, Carroll M, Catchpole A, Chiu C, McShane H; COV-CHIM01 study team. Jackson S, et al. Lancet Microbe. 2024 Apr 26:S2666-5247(24)00025-9. doi: 10.1016/S2666-5247(24)00025-9. Online ahead of print. Lancet Microbe. 2024. PMID: 38703782 Free article.
1,097 results